Chair/Online Presenter: Paul Y. Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University School of Medicine Indianapolis, IN
Content Development Faculty: Douglas T. Dieterich, MD Professor of Medicine Department of Medicine The Mount Sinai School of Medicine New York, NY Paul J. Pockros, MD Director, Liver Disease Center of the Division of Gastroenterology/Hepatology Director, SC Liver Research Consortium Scripps Clinic Director of Clinical Research Scripps Translational Science Institute La Jolla, CA
CCME Reviewer: Barry Zingman, MD Medical Director, AIDS Center Clinical Director, Infectious Diseases Montefiore Medical Center Bronx, NY
AMA PRA Category 1 Credit TM Medium
THIS PROGRAM WAS FIRST PRESENTED AS 11 LIVE GRAND ROUND MEETINGS THROUGHOUT THE COUNTRY STARTING MARCH 26, 2013. IF YOU HAVE ALREADY RECEIVED CREDIT DURING ONE OF THE LIVE MEETINGS, YOU ARE INELIGIBLE TO RECEIVE CREDIT FOR THIS ENDURING ACTIVITY.
Chronic hepatitis C virus (HCV) infection is responsible for approximately 8000 to 10 000 deaths annually in the United States. Individuals with chronic HCV infection experience a reduced health-related quality of life and have a reduced overall life expectancy by approximately 8 to 12 years. Individuals infected with HCV may not have symptoms for decades; thus, this epidemic is known as a “silent” epidemic. Of those infected with acute HCV, approximately 75% to 85% will progress to chronic HCV infection.
Over the next 2 decades, the public health burden from chronic HCV is predicted to increase substantially as patients who are currently asymptomatic or have relatively mild disease begin to experience more of the serious complications resulting from chronic HCV infection. The CDC emphasizes that mortality due to HCV has risen dramatically, overtaking deaths due to HIV in 2006.
Recent major advances in the treatment of chronic HCV infection include the development and approval of direct-acting antiviral (DAA) agents, leading to new standards of care and a better outlook for patients. Additional therapies under investigation and the identification of novel targets for antiviral therapy offer an opportunity for additional improvements in the treatment of chronic HCV infection, including potential interferon-free regimens.
. Target Audience
This activity, developed by experts in hepatitis C, has been designed for hepatologists, infectious disease specialists, primary care/internal medicine physicians, hospitalists, and other health care clinicians interested and involved in the treatment of patients with HCV.
Upon completion of this educational activity, the participant should be able to:
Discuss the shift in HCV patient demographics and the growing importance of screening.
Review strategies for individualizing HCV therapy based on patient and virologic factors.
Describe factors that can influence the achievement of a sustained virologic response.
Summarize strategies designed to counteract the side effects of HCV drugs.
Identify key data from clinical trials of emerging agents for treatment of HCV.
The “Conflict of Interest Disclosure Policies” of Albert Einstein College of Medicine of Yeshiva University require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
The Albert Einstein College of Medicine of Yeshiva University (Einstein) also require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
Contributors whose COIs are irresolvable are not permitted to participate in Einstein CME activities.
Paul Kwo, MD:
Grant/Research: Merck, Vertex, Gilead, BMS, Abbott, Roche
Consultant: Merck, Vertex, Gilead, Novartis
Douglas Dieterich, MD:
Grant/Research: Gilead, BI, Abbott, BMS
Consultant: Gilead, BI, Novartis, Roche, Genentech
Paul Pockros, MD:
Grant Research: BI, Vertex
Consultant/Speakers Bureau: Vertex
The staff of CCME of Albert Einstein College of Medicine have no disclosures to report with any commercial interests other than the following:
Steven Jay Feld, or a member of his household own securities in: Bioheart, Inc.; Chelsea Therapeutics, Inc.; Depomed; and Pharmacopeia, Inc.
Dr. Barry S. Zingman has no disclosures.
Dr. Sara Thier (MCM Education Senior Medical Writer/Editor) has no disclosures. Credit Statements
ACCME ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center, and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
ACCME CREDIT DESIGNATION STATEMENT: Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in each activity.
Commercial Support Statements
Supported by an independent education grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Supported by an independent education grant from Vertex Pharmaceuticals, Inc.
There are no fees for participating in or receiving credit for this online educational activity.
Participants must view/listen to the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing education credit. Credit will be awarded for a score of 80% or better, and a statement may be printed immediately after passing the post-test online.
Review the intended audience, learning objectives, and author disclosures.
Study the educational activity, including the question bank.
Once completed, please proceed to the post-activity survey, and post-test.
Online, choose the best answer to each post-test question. Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
Presented by Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, and MCM Education.
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, Boehringer Ingelheim, or Vertex. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.